Showing 1 - 7 of 7
Persistent link: https://www.econbiz.de/10003543703
Persistent link: https://www.econbiz.de/10010200106
Persistent link: https://www.econbiz.de/10010248454
We estimate a model of drug demand and supply that incorporates insurance, advertising, and competition between branded and generic drugs within and across therapeutic classes. We use data on antiulcer drugs from 1991 to 2010. Our simulations show generics and "me-too" drugs each increased...
Persistent link: https://www.econbiz.de/10010250679
We estimate a model of drug demand and supply that incorporates insurance, advertising, and competition between branded and generic drugs within and across therapeutic classes. We use data on antiulcer drugs from 1991 to 2010. Our simulations show generics and ``me-too'' drugs each increased...
Persistent link: https://www.econbiz.de/10013074647
We estimate a model of drug demand and supply that incorporates insurance, advertising, and competition between branded and generic drugs within and across therapeutic classes. We use data on antiulcer drugs from 1991 to 2010. Our simulations show generics and ``me-too'' drugs each increased...
Persistent link: https://www.econbiz.de/10012459141
Patents for several blockbuster biological products are expected to expire soon. The Food and Drug Administration is examining whether biologics can and should be treated like pharmaceuticals with regard to generics. In contrast with pharmaceuticals, which are manufactured through chemical...
Persistent link: https://www.econbiz.de/10014049980